Evidence map›Paper›PMID 42458140›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026

Correction: Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801.

Pablo Cerezuela-Fuentes, Antonio Piñero-Madrona, Eva Muñoz-Couselo, José Luis Manzano, Miguel-Ángel Berciano-Guerrero, Margarita Majem, Enrique Espinosa, Ainara Soria, Pablo Ayala de Miguel, Almudena García Castaño and 16 more

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors.

Pablo Cerezuela-FuentesMedical Oncology Department, Instituto Murciano de Investigación Sanitaria (IMIB), Hospital Clínico Universitario Virgen de la Arrixaca, Ciudad de Murcia, Spain. pcerezuelaf@seom.org.ORCID http://orcid.org/0000-0002-4886-4831
Antonio Piñero-MadronaDepartment of Surgery, Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-Arrixaca, Ciudad de Murcia, Spain.
Eva Muñoz-CouseloMedical Oncology Department, Hospital Universitari Vall d'Hebron y Vall D'hebron Institute of Oncology (VHIO), Barcelona, Spain.
José Luis ManzanoMedical Oncology Department, Instituto Catalán de Oncología, ICO-Badalona, H. Germans Trias i Pujol, Badalona, Spain.
Miguel-Ángel Berciano-GuerreroUnidad Intercentros de Oncología, Hospitales Universitarios Regional y Virgen de la Victoria (HURyVV), Instituto de Investigaciones Biomédicas de Málaga (IBIMA), Málaga, Spain.
Margarita MajemMedical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Enrique EspinosaMedical Oncology Department, Hospital Universitario La Paz, CIBERONC, Madrid, Spain.
Ainara SoriaMedical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Pablo Ayala de MiguelMedical Oncology Department, Hospital Universitario San Pedro de Alcántara, Cáceres, Spain.
Almudena García CastañoMedical Oncology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
Guillermo CrespoMedical Oncology Department, Hospital Universitario de Burgos, Burgos, Spain.
Lourdes Gutiérrez SanzMedical Oncology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain.
Carlos Aguado de la RosaMedical Oncology Department, Hospital Universitario Clínico San Carlos, Madrid, Spain.
Luis Antonio Fernández-MoralesMedical Oncology Department, Hospital Universitari Parc Taulí, Sabadell, Spain.
Teresa PuértolasMedical Oncology Department, Hospital Universitario Miguel Servet, Saragossa, Spain.
Joaquín Fra RodríguezMedical Oncology Department, Hospital Universitario Río Hortega, Valladolid, Spain.
María Rodríguez de la BorbollaMedical Oncology Department, Hospital Universitario de Valme, Seville, Spain.
Lorena BellidoMedical Oncology Department, Complejo Asistencial Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain.
Rafael López CastroMedical Oncology Department, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.
Victor Navarro PérezMedical Oncology Department, Hospital Costa del Sol, Marbella, Spain.
Francisco Ramón García ArroyoMedical Oncology Department, Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain.
José Carlos Villa GuzmánMedical Oncology Department, Hospital General de Ciudad Real, Ciudad Real, Spain.
Begoña Campos BaleaMedical Oncology Department, Hospital Universitario Lucus Augusti, Lugo, Spain.
Berta HernándezMedical Oncology Department, Hospital Universitario La Princesa, Madrid, Spain.
Salvador Martín AlgarraMedical Oncology Department, Clínica Universidad de Navarra, Pamplona, Spain.
Iván Márquez-RodasMedical Oncology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42458140

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.